{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SoC&page=24",
    "query": {
      "intervention": "SoC",
      "page": 24
    },
    "page_size": 10
  },
  "pagination": {
    "page": 24,
    "page_size": 10,
    "total_count": 1401,
    "total_pages": 141,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SoC&page=25&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SoC&page=23&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T11:36:40.463Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07155187",
      "title": "A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "c-MET"
      ],
      "interventions": [
        {
          "name": "Telisotuzumab Adizutecan",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        },
        {
          "name": "Osimertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 490,
      "start_date": "2025-12-10",
      "completion_date": "2030-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-27T11:36:40.463Z",
      "location_count": 16,
      "location_summary": "Springdale, Arkansas • Duarte, California • Irvine, California + 13 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07155187"
    },
    {
      "nct_id": "NCT04794621",
      "title": "Electroceutical Dressing Technology (EDT) Against Wound Microbial Biofilm Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Wound Heal"
      ],
      "interventions": [
        {
          "name": "Electroceutical Dressing Technology-EDThi",
          "type": "DEVICE"
        },
        {
          "name": "Adding EDTlo (Procellera®) for 3 weeks after use of EDThi",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2021-06-03",
      "completion_date": "2023-07-07",
      "has_results": false,
      "last_update_posted_date": "2023-10-03",
      "last_synced_at": "2026-10-27T11:36:40.463Z",
      "location_count": 3,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04794621"
    },
    {
      "nct_id": "NCT06694454",
      "title": "Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)",
        "Carcinoma, Non-Small Cell Lung",
        "Non-Small Cell Lung Carcinoma",
        "Non Small Cell Lung Cancer",
        "Non Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "azacytidine",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "durvalumab",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-10-29",
      "completion_date": "2034-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-10-27T11:36:40.463Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06694454"
    },
    {
      "nct_id": "NCT03260894",
      "title": "Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Cell Carcinoma (RCC)"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        },
        {
          "name": "Pazopanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 129,
      "start_date": "2017-12-07",
      "completion_date": "2025-06-04",
      "has_results": true,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-27T11:36:40.463Z",
      "location_count": 25,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03260894"
    },
    {
      "nct_id": "NCT05780541",
      "title": "PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "PF-07304814",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Remdesivir",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2021-09-15",
      "completion_date": "2023-07-14",
      "has_results": true,
      "last_update_posted_date": "2024-02-09",
      "last_synced_at": "2026-10-27T11:36:40.463Z",
      "location_count": 31,
      "location_summary": "Chula Vista, California • Los Angeles, California • Mather, California + 23 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mather",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05780541"
    },
    {
      "nct_id": "NCT07281027",
      "title": "COMparison Between Anakinra and Tocilizumab in NORSE - \"COMBAT-NORSE\"",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "New Onset Refractory Status Epilepticus",
        "New-Onset Refractory Status Epilepticus",
        "Febrile Infection-Related Epilepsy Syndrome (FIRES)"
      ],
      "interventions": [
        {
          "name": "Anakinra",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Standard medical treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 438,
      "start_date": "2026-12-01",
      "completion_date": "2030-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-27T11:36:40.463Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07281027"
    },
    {
      "nct_id": "NCT07187479",
      "title": "Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Kidney Disease (Stages 4 and 5)",
        "Kidney Disease",
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Physiologic Insulin Resensitization (PIR)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Well Cell Global",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2025-10-14",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-27T11:36:40.463Z",
      "location_count": 2,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07187479"
    },
    {
      "nct_id": "NCT04694846",
      "title": "Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lung Non-Small Cell Carcinoma",
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Nicotine Replacement",
          "type": "DRUG"
        },
        {
          "name": "Bupropion Hydrochloride Controlled-release",
          "type": "DRUG"
        },
        {
          "name": "Varenicline",
          "type": "DRUG"
        },
        {
          "name": "Tobacco Cessation Counseling",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality of Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Best Practice",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2020-08-19",
      "completion_date": "2024-08-16",
      "has_results": false,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-10-27T11:36:40.463Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04694846"
    },
    {
      "nct_id": "NCT07290803",
      "title": "This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2025-11-17",
      "completion_date": "2034-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-27T11:36:40.463Z",
      "location_count": 46,
      "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 43 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07290803"
    },
    {
      "nct_id": "NCT05155891",
      "title": "Investigation of Prostate Artery Embolization Compared to Holmium Laser Enucleation of Prostate",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Benign Prostatic Hyperplasia"
      ],
      "interventions": [
        {
          "name": "Embosphere Microspheres",
          "type": "DEVICE"
        },
        {
          "name": "HoLEP Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "50 Years and older · Male only"
      },
      "enrollment_count": 45,
      "start_date": "2022-06-17",
      "completion_date": "2027-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-10-27T11:36:40.463Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05155891"
    }
  ]
}